Yaling Hu

5.4k total citations · 2 hit papers
21 papers, 1.7k citations indexed

About

Yaling Hu is a scholar working on Infectious Diseases, Health and Molecular Biology. According to data from OpenAlex, Yaling Hu has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 5 papers in Health and 4 papers in Molecular Biology. Recurrent topics in Yaling Hu's work include SARS-CoV-2 and COVID-19 Research (16 papers), COVID-19 Clinical Research Studies (9 papers) and SARS-CoV-2 detection and testing (6 papers). Yaling Hu is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (16 papers), COVID-19 Clinical Research Studies (9 papers) and SARS-CoV-2 detection and testing (6 papers). Yaling Hu collaborates with scholars based in China, United States and South Korea. Yaling Hu's co-authors include Weidong Yin, Qiang Gao, Xiangxi Wang, Jingxin Li, Yuansheng Hu, Fengcai Zhu, Zhen Chen, Yan Song, Changgui Li and Minnan Yang and has published in prestigious journals such as Clinical Infectious Diseases, Frontiers in Immunology and The Lancet Infectious Diseases.

In The Last Decade

Yaling Hu

21 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

2020 937 citations Yanjun Zhang, Gang Zeng et al. The Lancet Infectious Diseases profile →
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

2021 364 citations Zhiwei Wu, Yaling Hu et al. The Lancet Infectious Diseases profile →

Peers

Yaling Hu

HEALT

IMMUN

Rong Tang China

Hongxing Pan China

Carmit Rubin Israel

Gang Zeng China

Minnan Yang China

Sharon Alroy‐Preis Israel

Weixiao Han China

Doron Netzer Israel

Rong Tang China

Yaling Hu

929 ×0.6

328 ×0.7

HEALT

150 ×0.7

126 ×0.7

IMMUN

103 ×0.6

Citations per year, relative to Yaling Hu Yaling Hu (= 1×) peers Rong Tang

Countries citing papers authored by Yaling Hu

Since Specialization

Citations

This map shows the geographic impact of Yaling Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaling Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaling Hu more than expected).

Fields of papers citing papers by Yaling Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaling Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaling Hu. The network helps show where Yaling Hu may publish in the future.

Co-authorship network of co-authors of Yaling Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Yaling Hu. A scholar is included among the top collaborators of Yaling Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaling Hu. Yaling Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Chaoying, Jinxia Chen, X. Sunney Xie, et al.. (2024). Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial. Pharmaceutics. 17(1). 43–43. 2 indexed citations

Guo, Ziyi, Wenyuan Liu, Lin Zhang, et al.. (2024). Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 Pathway. Chinese Journal of Integrative Medicine. 31(5). 422–433. 4 indexed citations

Shan, Ke-Jia, Changcheng Wu, Xiaolu Tang, et al.. (2023). Molecular Evolution of Protein Sequences and Codon Usage in Monkeypox Viruses. Genomics Proteomics & Bioinformatics. 22(1). 12 indexed citations

Hu, Jialei, Yueyue Liu, Shuo Liu, et al.. (2023). Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial. Frontiers in Immunology. 14. 1241153–1241153. 4 indexed citations

Xu, Kangwei, et al.. (2023). The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC–MS. Vaccines. 11(5). 1002–1002. 1 indexed citations

Yang, Haitao, Tingyu Zhuang, Τao Zhu, et al.. (2023). Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older: A Dosing Interval Study — Yunnan Province, China, 2021–2022. China CDC Weekly. 5(6). 125–130. 2 indexed citations

Cao, Yunlong, Biao Kan, Xiaoliang Sunney Xie, et al.. (2023). Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study — Hohhot City, Inner Mongolia Autonomous Region, China, 2022. China CDC Weekly. 5(10). 218–222. 5 indexed citations

Cao, Lei, Nan Wang, Zhe Lv, et al.. (2023). Insights into varicella-zoster virus assembly from the B- and C-capsid at near-atomic resolution structures. 2(2). 64–74. 5 indexed citations

Li, Siqi, Xiaoli Wang, Li Li, et al.. (2022). Factors Associated with SARS-CoV-2 Repeat Positivity — Beijing, China, June–September 2020. China CDC Weekly. 4(5). 88–95. 4 indexed citations

10.

Zhao, Yingchi, Ming Kuang, Junhong Li, et al.. (2021). Publisher Correction: SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Research. 31(7). 825–825. 29 indexed citations

11.

Feng, X Y, Jiming Yin, Jiaying Zhang, et al.. (2021). Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Frontiers in Immunology. 12. 614436–614436. 12 indexed citations

12.

Shen, Yinfeng, et al.. (2021). Relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and patient immunity after 6 month hospital discharge. Inflammation Research. 70(2). 241–247. 4 indexed citations

13.

Li, Li, Siqi Li, Yang Pan, et al.. (2021). An Immunocompetent Patient with High Neutralizing Antibody Titers Who Shed COVID-19 Virus for 169 days — China, 2020. China CDC Weekly. 3(32). 688–691. 7 indexed citations

14.

Yu, Yuanling, Xiaohong Wu, Jianhui Nie, et al.. (2021). The first Chinese national standards for SARS-CoV-2 neutralizing antibody. Vaccine. 39(28). 3724–3730. 9 indexed citations

15.

An, Xuedong, Xi Xu, Mingzhong Xiao, et al.. (2021). Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial. Frontiers in Medicine. 8. 728055–728055. 30 indexed citations

16.

Wu, Zhiwei, Yaling Hu, Miao Xu, et al.. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21(6). 803–812. 364 indexed citations breakdown →

17.

Fadlyana, Eddy, Kusnandi Rusmil, Rodman Tarigan, et al.. (2021). A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. Vaccine. 39(44). 6520–6528. 82 indexed citations

18.

Wang, Xiaoli, Xianghua Guo, Qianqian Xin, et al.. (2020). Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clinical Infectious Diseases. 71(10). 2688–2694. 193 indexed citations

19.

Zhang, Yanjun, Gang Zeng, Hongxing Pan, et al.. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21(2). 181–192. 937 indexed citations breakdown →

20.

Gu, Wei, Yuemei Hu, Yuansheng Hu, et al.. (2018). A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. Expert Review of Vaccines. 17(3). 257–262. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rong Tang Breakdown of academic impact, for papers by Hongxing Pan Breakdown of academic impact, for papers by Carmit Rubin Breakdown of academic impact, for papers by Gang Zeng Breakdown of academic impact, for papers by Minnan Yang Breakdown of academic impact, for papers by Sharon Alroy‐Preis Breakdown of academic impact, for papers by Weixiao Han Breakdown of academic impact, for papers by Doron Netzer